Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1

• Published in: Neuro-endocrinology letters Vol. 28; no. 6; p. 761
• Main Authors: Kotaska, Karel, Petrak, Borivoj, Kukacka, Jiri, Kraus, Josef, Prusa, Richard
• Format: Journal Article
• Language: English
• Published: Sweden 01-12-2007
• Subjects: Adolescent; Adult; Antibody Formation - immunology; Biomarkers - blood; Biomarkers, Tumor - blood; Central Nervous System Neoplasms - blood; Central Nervous System Neoplasms - complications; Central Nervous System Neoplasms - immunology; Child; Child, Preschool; Female; Humans; Immunoglobulin G - blood; Immunoglobulin M - blood; Infant; Male; Neurofibroma, Plexiform - blood; Neurofibroma, Plexiform - complications; Neurofibroma, Plexiform - immunology; Neurofibromatosis 1 - blood; Neurofibromatosis 1 - complications; Neurofibromatosis 1 - immunology; Optic Nerve Glioma - blood; Optic Nerve Glioma - complications; Optic Nerve Glioma - immunology; Phosphopyruvate Hydratase - blood; Sensitivity and Specificity; Skin Neoplasms - blood; Skin Neoplasms - complications; Skin Neoplasms - immunology; Statistics, Nonparametric; Vimentin - immunology
• ISSN: 0172-780X

The aim of the study was to investigate the relationship of serum levels of neuron-specific enolase, anti-vimentin IgG, and anti-vimentin IgM antibodies in patients with neurofibromatosis type 1 and associated tumors (optic glioma, and plexiform neurofibroma).
Measurement of neuron-specific enolase and anti-vimentin antibodies were performed in 131 children and adolescents (67 males, mean age 10 years, range 4-19 years; 64 females, mean age 11 years, range 1-20 years) with three different forms of neurofibromatosis type 1 and in control group of 40 individuals (20 males, mean age 9 years, range 1-19 years and 20 females, mean age 12 years, range 3-18 years).
Anti-vimentin IgG, IgM antibodies and NSE showed similar ability to distinguish between neurofibromatosis type 1 and tumors associated with neurofibromatosis type 1. (AUC=0.57, AUC=0.52 and AUC=0.59 respectively). NSE showed better diagnostic efficiency (AUC=0.68) than the anti-vimentin IgG and anti-vimentin IgM. (AUC=0.63 and AUC=0.56 respectively). Anti-vimentin IgG and IgM antibodies showed higher sensitivity (87.5% and 87.2%) at the cut off value than the NSE (54%). On the contrary, NSE showed higher specificity at the cut off value than both the anti-vimentin IgG and IgM (71% vs. 22.5% and 16% respectively).
Anti-vimentin IgG and IgM and neuron-specific enolase are relevant markers in investigation of the patients with neurofibromatosis type 1 and associated tumors.